Introduction to Bi-directional Tachycardia Drugs
The bi-directional tachycardia drugs are used for the treatment of cardiac disorders in adult patients. Bi-directional tachycardia is a regular ventricular tachyarrhythmia that makes your heart beat more than 100 times per minute. It is characterized by a beat-to-beat alternation of the frontal QRS axis. The bi-directional tachycardia can disrupt normal heart function and can lead to serious complications including heart failure, stroke, sudden cardiac arrest or even death. It is most likely to affect people who smoke, consume excess alcohol, or have a lot of caffeine. In some cases, it’s linked to heart attacks.
Market Size and Forecast
Rising cases of patients with cardiac diseases coupled with the advancements in healthcare as well as improvements in treatment therapies are the significant factors boosting the market growth. The bi-directional tachycardia drugs market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The market is segmented by distribution channel into hospitals, clinics, research laboratories and retail pharmacies. Among these segments, the segment for hospitals is anticipated to hold the leading share in the market on account of wide-scale availability of bi-directional tachycardia drugs used for the patient’s treatment at the hospital only.
Increasing Prevalence of Cardiac Disorders Globally to Boost the Market Growth
Rising incidences of cardiovascular disorders across the world and related diseases such as arrhythmia, heart attacks and strokes is the key dynamic factor propelling the growth of bi-directional tachycardia drugs. According to World Health Organization (WHO), in 2016, an estimated 17.9 million people died from cardiovascular diseases (CVDs) which represents 31% of all deaths worldwide. Moreover, growing geriatric population diagnosed with heart diseases and changing lifestyles are other factors are anticipated to significantly expand the bi-directional tachycardia drugs market. CLICK TO DOWNLOAD SAMPLE REPORT
Huge Investment in Healthcare R&D to Drive the Market Growth
The healthcare development all over the world is improving at a fast pace owing to the increasing number of cases of various diseases which results in a growing demand for better healthcare services, facilities and equipment at clinics and hospitals. The growing research activities for treatment methods at research laboratories further fuels the healthcare industry. On the back of such factors, the global bi-directional tachycardia drugs market is predicted to grow over the forecast period.
High Cost and Side-Effects of Drugs to Hamper the Market Growth
Despite the improving healthcare infrastructure, there is a high cost involved in the drugs related to treatment of cardiovascular diseases. Further, there are major side effects associated with this drugs post medication. This is estimated to hinder the growth of bi-directional tachycardia drugs market in the future.
Our in-depth analysis of the bi-directional tachycardia drugs market includes the following segments:
By Route of Administration
By Distribution Channel
- Research Laboratories
- Retail Pharmacies
On the basis of regional analysis, the bi-directional tachycardia drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
The market for bi-directional tachycardia drugs in North America is anticipated to hold the largest share in the market on account of presence of leading market players in the region which manufacture and market bi-directional tachycardia drugs. Moreover, growing healthcare expenditure and support from government in implementation of advanced therapeutics coupled with the rise in patients with cardiovascular disorders in the region further increases the product demand. The bi-directional tachycardia drugs market in Asia Pacific region is predicted to grow at the highest rate during the forecast period as a result of developing healthcare infrastructure and growing research activities in the region. Additionally, the prevalence of chronic diseases along with the rise in public awareness about early diagnosis of heart disease like tachycardia, especially in countries such as China, India and Japan further raise the demand for bi-directional tachycardia drugs.
The bi-directional tachycardia drugs market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Top Featured Companies Dominating the Market
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline plc.
- Merck and Co., Inc.
- Bayer AG